Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs iShares MSCI Indonesia ETF (EIDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs iShares MSCI Indonesia ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while iShares MSCI Indonesia ETF trades at $12. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, iShares MSCI Indonesia ETF nearer its low. Which is the better fit depends on your goals.
| BIO | EIDO | |
|---|---|---|
Market Cap | $8.02B | — |
Sector | Health | — |
52-Week High | $339.75 | $19.22 |
52-Week Low | $241.71 | $10.80 |
Enterprise Value | $7.84B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
EIDO, the iShares MSCI Indonesia ETF, trades at $11.98, up 1.1% on the day, but technical indicators signal a bearish trend with moving averages and RSI_6 suggesting caution. Key financial ratios are unavailable, but recent news highlights Indonesia's economic initiatives, including a $15 billion AI-integrated free-meal program and central bank rate hikes to support the rupiah. The ETF's dividend dropped 27% in 2025, indicating potential income instability for investors.
The outlook for EIDO is mixed, with opportunities from Indonesia's GDP growth potential but risks from currency volatility and dividend cuts. Investors face headwinds from bearish technical signals and macroeconomic pressures, requiring careful assessment of emerging market exposure amid fluctuating sentiment and limited fundamental data.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →
